BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 511372)

  • 1. Realities in evaluating the clinical uses of sorbent hemoperfusion.
    Winchester JF; Gelfand MC; Knepshield JH; Schreiner GE
    Int J Artif Organs; 1979 Nov; 2(6):310-4. PubMed ID: 511372
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemoperfusion in 1981.
    Chang TM
    Contrib Nephrol; 1982; 29():11-22. PubMed ID: 7042197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of hemoperfusion in children. Past, present, and future.
    Papadopoulou ZL; Novello AC
    Pediatr Clin North Am; 1982 Aug; 29(4):1039-52. PubMed ID: 7050859
    [No Abstract]   [Full Text] [Related]  

  • 4. Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure.
    Chang TM
    Kidney Int Suppl; 1975 Feb; (3):387-92. PubMed ID: 1099317
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood purification by haemoperfusion.
    Klinkmann H; Falkenhagen D; Courtney JM
    Int J Artif Organs; 1979 Nov; 2(6):296-308. PubMed ID: 511371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoperfusion: present and future.
    Gelfand MC
    J Dial; 1979; 3(1):1-9. PubMed ID: 469100
    [No Abstract]   [Full Text] [Related]  

  • 7. Present and future uses of hemoperfusion with sorbents.
    Winchester JF; Gelfand MC; Knepshield JH; Schreiner GE
    Artif Organs; 1978 Nov; 2(4):353-8. PubMed ID: 743004
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of comatose patients by extracorporeal hemoperfusion with activated charcoal].
    Lie TS; Kim WI; Rommelsheim K; Holst A
    MMW Munch Med Wochenschr; 1976 Jul; 118(29-30):945-8. PubMed ID: 820984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibilities to avoid adsorption of physiological substances during charcoal hemoperfusion (author's transl)].
    Gundermann KJ; Lie TS
    Res Exp Med (Berl); 1978 Jul; 173(1):105-11. PubMed ID: 684283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1978 perspective of hemoperfusion.
    Chang TM
    Artif Organs; 1978 Nov; 2(4):359-62. PubMed ID: 743005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemoperfusion in the treatment of endogenous and exogenous poisoning].
    Trznadel K
    Pol Tyg Lek; 1978 Jan; 33(5):203-5. PubMed ID: 652646
    [No Abstract]   [Full Text] [Related]  

  • 12. [Charcoal-activated hemoperfusion--an important adjunct therapeutic method in severe poisoning].
    Voigtmann R; von Baeyer H; Sieberth HG
    Med Welt; 1976 Apr; 27(16):752-7. PubMed ID: 1272030
    [No Abstract]   [Full Text] [Related]  

  • 13. Panel conference. Adsorbent hemoperfusion for blood purification.
    Chang TM; Winchester JF; Rosenbaum J; Saito A; Stefoni S; Shu C; Gurland HL
    Trans Am Soc Artif Intern Organs; 1980; 26():593-7. PubMed ID: 7245556
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemoperfusion for uremia: past, present, and future.
    Winchester JF; Ash SR
    Kidney Int Suppl; 1985 Dec; 17():S127-30. PubMed ID: 3867782
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemoperfusion based on artificial cells for aluminium and iron removal, immunosorption, fulminant hepatic failure, uremia, poisoning and metabolic assists.
    Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):285-8. PubMed ID: 3781657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of haemocol hemoperfusion].
    Pall H
    Wien Klin Wochenschr Suppl; 1978; 89():1-12. PubMed ID: 351974
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemoperfusion with gelatin-encapsulated charcoal.
    Wu ZG; Cai ZH; Lu ZN; Liao LT
    Chin Med J (Engl); 1984 Apr; 97(4):251-6. PubMed ID: 6434256
    [No Abstract]   [Full Text] [Related]  

  • 18. [Extracorporeal hemosorption, an effective means of controlling exogenous and endogenous intoxications].
    Vlasenko AN
    Klin Med (Mosk); 1980 Jun; 58(6):17-22. PubMed ID: 6995710
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemoperfusion alone and in series with ultrafiltration or dialysis for uremia, poisoning and liver failure.
    Chang TM
    Kidney Int Suppl; 1976 Dec; (7):S305-11. PubMed ID: 1070552
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective date of requirement for premarket approval for transilluminator for breast evaluation and sorbent hemoperfusion system (SHS) devices for the treatment of hepatic coma and metabolic disturbances; reclassification of SHS and devices for the treatment of poisoning and drug overdose. Final order.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jan; 79(12):3088-94. PubMed ID: 24443766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.